(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the pending confirmations of three officials of the U.S. Department of Health and Human Services (HHS): Chiquita Brooks-LaSure, nominee for Administrator for
(Washington, D.C.) — Pharmaceutical Care Management Association President and CEO Mark Merritt issued the following statement on the Administration’s announcement to provide Medicare Part D plans additional flexibility in designing Medicare Part D formularies around medical indications. “While PCMA is
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released a new, first-of-its-kind, progress report on the work PCMA member pharmacy benefit companies are doing to deepen the industry’s commitment to promote health equity and reduce health disparities. This
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021 report, that PBM-negotiated rebates are not correlated with the list prices set by drug companies. The report also finds that “drug companies have
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on a new advertising campaign against Section 306 in S. 1895, the “Lower Health Care Costs Act:”
As a so-called “delinking” measure continues to be discussed in Congress, specifically in the Medicare Part D program, it’s important lawmakers understand that this policy does not actually reduce costs in any way. Members and staff need to ask themselves,
Misguided Legislation Targets Pharmacy Benefits That Save Employers and Patients an Average of $1,000 Per Person Each Year and Undermines Market Forces in Health Care In case you missed it, leading economic experts and competition watchdogs have overwhelmingly expressed concern
With the recent launch of a new adalimumab biosimilar, the U.S. biosimilar market is becoming more competitive, increasing the potential for these more affordable options to play a critical role in helping to lower prescription drug costs for Americans. As biosimilar competition
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market and have advocated for policy changes that will increase generic and biosimilar uptake and put an end to brand manufacturers’ tactics to extend exclusivity on brand-name biologics. As more
©2024 PCMA. All Rights Reserved.
